Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Prostate cancer" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 51
Tytuł:
Apalutamide as a therapeutic option in case of local failure in the nmCRPC
Autorzy:
Stankiewicz, Magdalena
Powiązania:
https://bibliotekanauki.pl/articles/22676730.pdf
Data publikacji:
2023-04-01
Wydawca:
Medical Education
Tematy:
prostate cancer
castration resistance
apalutamide
Opis:
Apalutamide is a non-steroidal selective androgen receptor inhibitor approved for the treatment of high-risk non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. The paper describes a case of a patient diagnosed with prostate cancer with a long-term course of the disease. The patient was diagnosed with a non-metastatic castration-resistant stage 18 years after primary treatment. Systemic treatment with apalutamide was recommended. Initially, the treatment was carried out as part of the extended access to apalutamide program and from March 2022 as part of the B.56 drug program. The study presents the effectiveness and safety of the therapy in a 12-month follow-up period and discusses controversial aspects of the patient's previous treatments.
Źródło:
OncoReview; 2023, 13, 1; 13-19
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Tetraspanin CD151 mediates communication between PC3 prostate cancer cells and osteoblasts
Autorzy:
Grudowska, Alicja
Czaplińska, Dominika
Polom, Wojciech
Matuszewski, Marcin
Sądej, Rafał
Składanowski, Andrzej
Powiązania:
https://bibliotekanauki.pl/articles/1038698.pdf
Data publikacji:
2017
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
CD151
prostate cancer
osteoblasts
Opis:
Invasion and migration of cancer cells are crucial for the formation of secondary lesions. These require activation of signalling cascades modulated by the number of regulatory molecules. One such molecule is CD151, a member of evolutionary conserved tetraspanin family. CD151 is involved in cell adhesion, motility and cancer progression due to formation of complexes with laminin-binding integrins and regulation of growth factor receptors function (e.g. HGFR, TGFβR, EGFR). Recent studies point to correlation between CD151 expression and high tumour grade in prostate cancer (PCa). Herein, we investigated a possible role of CD151 in communication between PC3 cancer cells and either cancer-associated fibroblasts (CAFs) or osteoblasts, an interplay which is significant for metastasis. The analysis showed that although CAFs strongly enhanced both migration and invasion of PC3 prostate cancer cells, the effect was not dependent on CD151. On the other hand, CD151 was found to promote 3D migration as well as invasive growth in response to osteoblasts-secreted growth factors. Obtained data revealed that knockdown of CD151 abolished activation of pro-migratory/pro-survival kinases (i.e FAK, Src, HSP27) triggered by osteoblasts, along with expression of matrix metalloproteinase-13. This suggests that CD151 participates in communication between PC3 cells and bone microenvironment and the process can be considered as a significant step of PCa progression and metastasis.
Źródło:
Acta Biochimica Polonica; 2017, 64, 1; 135-141
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Time to treatment of prostate cancer patients
Autorzy:
Rucińska, Monika
Osowiecka, Karolina
Gałka, Szymon
Środa, Radosław
Wojciechowski, Piotr
Sugajska, Anna
Powiązania:
https://bibliotekanauki.pl/articles/1035802.pdf
Data publikacji:
2018
Wydawca:
Medical Education
Tematy:
prostate cancer
waiting for treatment
Opis:
Prostate cancer is one of the most common cancers in men. The incidence of prostate cancer increases systematically. The correlation between waiting time for oncological treatment and survival prognosis in prostate cancer is not clearly determined. The aim of the study was to estimate the waiting time from suspicion until prostate cancer diagnosis and treatment in Warmia and Mazury Voivodeship. Ninety-six consecutive prostate cancer patients treated with radical radiotherapy between November 2016 and June 2017 in the Department of Radiation Oncology of the Hospital of the Ministry of Internal Affairs with Warmia and Mazury Oncology Center in Olsztyn were included in the analysis. A questionnaire prepared especially for this study, and individual interviews with patients were used in the study. The obtained data was supplemented with medical records and hospital databases. In the case of twenty-nine men, the PSA concentration was measured due to urinary disorders, and the median time from symptoms until the first PSA test in that group was 168 days. The median time from PSA concentration > 4 ng/ml to biopsy of prostate cancer and start of treatment for all patients was 62 and 156 days, respectively. Hormone therapy was administered the quickest. A positive correlation was observed between the waiting time from histopathological confirmation of prostate cancer until treatment, and the distance from one’s place of residence to the oncological center (p < 0.05).
Źródło:
OncoReview; 2018, 8, 3; 86-93
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Prostate cancer in an elderly patient with a history of comorbidities
Autorzy:
Stryczyńska-Mirocha, Adriana
Mirocha, Martyna
Powiązania:
https://bibliotekanauki.pl/articles/22676694.pdf
Data publikacji:
2023-03-31
Wydawca:
Medical Education
Tematy:
prostate cancer
hormone therapy
nmCRPC
apalutamide
Opis:
Prostate cancer is the most common cancer in men in Poland. The choice of treatment method depends on many factors, including the stage of the disease, the patient's age, life expectancy, the presence of comorbidities and the general condition of the patient. Hormone therapy is one of the basic methods of prostate cancer treatment, both in adjuvant and palliative treatment. Castration-resistant prostate cancer is an incurable disease. However, the introduction of new hormonal drugs to therapy significantly extended the survival time of patients with relatively low harmfulness of therapy.
Źródło:
OncoReview; 2023, 13, 1; 3-5
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide treatment of locally advanced prostate cancer
Autorzy:
Palasik, Maria
Powiązania:
https://bibliotekanauki.pl/articles/22676859.pdf
Data publikacji:
2023-03-31
Wydawca:
Medical Education
Tematy:
prostate cancer
castration resistance
hormonotherapy
apalutamide
Opis:
Prostate cancer is most commonly diagnosed cancer in men. The choice of treatment method depends on many factors: the patient’s age, other patient’s diseases, psychophysical status and expected survival time. Hormonotherapy plays very important role in patients with no possible radical treatment. New therapies apply in patients with castration-resistant metastatic prostate cancer. First registered drug in patients with biochemical progression without metastases is apalutamide.
Źródło:
OncoReview; 2023, 13, 1; 31-32
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Triptorelin in androgen depravation therapy of advanced prostate cancer
Autorzy:
Kozikowski, Mieszko
Dobruch, Jakub
Powiązania:
https://bibliotekanauki.pl/articles/1035670.pdf
Data publikacji:
2019
Wydawca:
Medical Education
Tematy:
advanced prostate cancer
androgen depravation therapy
triptorelin
Opis:
Triptorelin as the luteinizing hormone releasing hormone (LHRH) analogue has its own place among other available forms of androgen-depravation therapy (ADT) of locally advanced and metastatic prostate cancer (PCa). Nowadays, in times of development of new therapies in castration-resistant PCa, ADT remains the back bone therapy, which may be supplemented with one of novel drugs. The results of basic research indicate, that apart from the main mechanism of action based on lowering a testosterone concentration to the castration level, triptorelin may have a direct inhibitory effect on tumor cells. Formulations of tryptorelin are available to administer as 1-month, 3-months and 6-months sustained-release forms that may be given intramuscularly or subcutaneously. Constant concentration of triptoreline is maintained by using special microspheres in drug production. Pharmacokinetic and pharmacodynamic properties of particular forms were extensively tested, which allows for safe usage and retain of predictable and high efficacy. Indicators of effective ADT are fast reduction and maintenance of the state of castration. This phenomenon translates into a decrease of the prostate-specific antigen and longer survival. Triptorelin successfully meets these objectives based on a number of phase I–III studies. There is a noticeable lack of comparative studies on effectiveness of particular ADT forms. This may stem from an assumption, that all LHRH analogues demonstrate similar effectiveness because of the class effect. However, some evidence highlight significant differences in efficacy among these drugs. Triptorelin compares especially favourably, particularly as a drug reducing the testosterone level to the lower recommended values (< 20 ng/dl). Side effect profile during the therapy with triptorelin is largely the result of inhibition of the hypothalamic pituitary-testicular axis. Hormonal disturbances linked to hipoandrogenism cause changes in lipid metabolism and glucose tolerance, which may influence the cardiovascular risk. This article is a review of key reports regarding triptorelin and a summary of the role that triptorelin plays in contemporary ADT in advanced PCa.
Źródło:
OncoReview; 2019, 9, 4; 73-87
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Obesity, Physical Activity and Prostate Cancer: An Overview
Autorzy:
Kruk, Joanna
Bernstein, Joshua
Aboul-Enein, Basil H.
Powiązania:
https://bibliotekanauki.pl/articles/2138482.pdf
Data publikacji:
2022
Wydawca:
Uniwersytet Szczeciński. Wydawnictwo Naukowe Uniwersytetu Szczecińskiego
Tematy:
Overweight
obesity
prostate cancer
inflammation
physical activity
Opis:
Obesity and a lack of sufficient physical activity (PA) are recognized as risk factors for most civilization diseases, including cancer. This study synthesized the current evidence evaluating the relationship between excess body weight and prostate cancer (PCa) in the relation to the disease risk, progression, and mortality, and identifies biological plausibility of the association. We also estimated the importance of PA in intentional body weight loss. Several electronic major databases to identify eligible articles were searched until March 2022. A total 22 observational articles, the literature on the underlying biological mechanisms, and the crucial evidence of a role of PA in body weight maintenance and reduction were reviewed. The available knowledge suggests that association between body mass index and PCa is conflicting. However, the most research consistently shown that overweight/obesity was associated with higher risk of high-grade PCa and dying of PCa. Overweight/obesity can promote high-grade PCa through increased levels of secreted adipokines, increased formation of proinflammatory agents, and reduced concentration of adiponectin, among others. Being obese may by also linked with a higher risk of mortality. Exercise can decrease these health consequences related with obesity and may be effective in reduction of PCa-specific mortality, however, there are relative few studies on PA and PCa prevention among obese individuals.
Źródło:
Central European Journal of Sport Sciences and Medicine; 2022, 38; 71-91
2300-9705
2353-2807
Pojawia się w:
Central European Journal of Sport Sciences and Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide in the treatment of a patient with non-metastatic castration-resistant prostate cancer
Autorzy:
Dziura, Robert
Powiązania:
https://bibliotekanauki.pl/articles/22676763.pdf
Data publikacji:
2023-03-31
Wydawca:
Medical Education
Tematy:
prostate cancer
castration-resistant
androgen receptor inhibitor
Opis:
The treatment of patients with prostate cancer, who do not qualify for the radical therapy is based on the use of surgical or pharmacological castration methods. The effectiveness of the so-called androgen deprivation tends to decrease over time. Even in the absence of distant metastases on imaging studies, the resistance for the hormonal castration may be developed. At this moment, the use of new generation androgen receptor inhibitors may reduce the risk of metastases or death. The paper presents a case report of a patient with prostate cancer without distant metastases who started therapy with apalutamide at the moment of developing re-sistance to the pharmacological castration.
Źródło:
OncoReview; 2023, 13, 1; 20-23
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide as a new option for postponing metastatic disease in hormone -resistant patients with biochemical recurrence in prostate cancer
Autorzy:
Dąbek, Bartosz
Powiązania:
https://bibliotekanauki.pl/articles/22676825.pdf
Data publikacji:
2023-04-04
Wydawca:
Medical Education
Tematy:
non-metastatic castration-resistant prostate cancer
apalutamide
Opis:
Treatment of non-metastatic castration-resistant prostate cancer is a radically new option for cancer patients. Novel anti-hormonal therapy not only improves metastasis free survival but overall survival times and positively impacts quality of life. This case shows how apalutamide lowered tPSA level and postponed metastatic disease.
Źródło:
OncoReview; 2023, 13, 1; 24-26
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
„Iron Heart”: Reversible Cause of Dilated Cardiomyopathy Secondary to Cardiac Toxicity in Elderly Patient with Myelodysplastic Syndrome
Autorzy:
Martin-Garcia, Ana
Alonso Fernandez de Gatta, Marta
Diez-Campelo, María
Martín-García, Agustín C.
Barreiro Pérez, Manuel
Diaz-Pelaez, Elena
López Cadenas, Félix
Sanchez, Pedro L.
Powiązania:
https://bibliotekanauki.pl/articles/1035672.pdf
Data publikacji:
2019
Wydawca:
Medical Education
Tematy:
advanced prostate cancer
androgen depravation therapy
triptorelin
Opis:
Triptorelin as the luteinizing hormone releasing hormone (LHRH) analogue has its own place among other available forms of androgen-depravation therapy (ADT) of locally advanced and metastatic prostate cancer (PCa). Nowadays, in times of development of new therapies in castration-resistant PCa, ADT remains the back bone therapy, which may be supplemented with one of novel drugs. The results of basic research indicate, that apart from the main mechanism of action based on lowering a testosterone concentration to the castration level, triptorelin may have a direct inhibitory effect on tumor cells. Formulations of tryptorelin are available to administer as 1-month, 3-months and 6-months sustained-release forms that may be given intramuscularly or subcutaneously. Constant concentration of triptoreline is maintained by using special microspheres in drug production. Pharmacokinetic and pharmacodynamic properties of particular forms were extensively tested, which allows for safe usage and retain of predictable and high efficacy. Indicators of effective ADT are fast reduction and maintenance of the state of castration. This phenomenon translates into a decrease of the prostate-specific antigen and longer survival. Triptorelin successfully meets these objectives based on a number of phase I–III studies. There is a noticeable lack of comparative studies on effectiveness of particular ADT forms. This may stem from an assumption, that all LHRH analogues demonstrate similar effectiveness because of the class effect. However, some evidence highlight significant differences in efficacy among these drugs. Triptorelin compares especially favourably, particularly as a drug reducing the testosterone level to the lower recommended values (< 20 ng/dl). Side effect profile during the therapy with triptorelin is largely the result of inhibition of the hypothalamic- pituitary-testicular axis. Hormonal disturbances linked to hipoandrogenism cause changes in lipid metabolism and glucose tolerance, which may influence the cardiovascular risk. This article is a review of key reports regarding triptorelin and a summary of the role that triptorelin plays in contemporary ADT in advanced PCa.
Źródło:
OncoReview; 2019, 9, 4; 88-91
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Apalutamide - 10 clinically important facts
Autorzy:
Juszczak, Kajetan
Drewa, Tomasz
Powiązania:
https://bibliotekanauki.pl/articles/2047224.pdf
Data publikacji:
2021-09-30
Wydawca:
Medical Education
Tematy:
apalutamide
prostate cancer
nonmetastatic
metastatic
CRPC
CSPC
Opis:
Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over time during hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. Apalutamide is used in the treatment of patients with non-metastatic as well as metastatic prostate cancer. This article presents the most important clinical facts about apalutamide.
Źródło:
OncoReview; 2021, 11, 3; 85-88
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The site of apalutamide in the treatment of prostate cancer
Autorzy:
Juszczak, Kajetan
Drewa, Tomasz
Powiązania:
https://bibliotekanauki.pl/articles/2047808.pdf
Data publikacji:
2021-09-22
Wydawca:
Medical Education
Tematy:
apalutamide
prostate cancer
nonmetastatic
metastatic
CRPC
CSPC
Opis:
Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over time during hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. The article presents the role of apalutamide in the treatment of prostate cancer and its effectiveness. Moreover, attention was drawn to the need for close cooperation between the urologist and the oncologist in order to optimize the treatment of a patient with progressive prostate cancer.
Źródło:
OncoReview; 2021, 11, 4; 120-122
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Survival in men diagnosed with prostate cancer in Poland in the years 2000 - 2014 compared to European Countries based on Concord-3
Autorzy:
Gliniewicz, A.
Dudek-Godeau, D.
Bielska-Lasota, M.
Powiązania:
https://bibliotekanauki.pl/articles/2087334.pdf
Data publikacji:
2020
Wydawca:
Narodowy Instytut Zdrowia Publicznego. Państwowy Zakład Higieny
Tematy:
prostate cancer
curability
mortality trend
cancer care
CONCORD-3
Opis:
Background. Wealthy countries have observed in recent decades a fast-growing number of prostate patients, who require treatment and long-term cancer care. This trend seems to be connected with some demographic changes such as aging societies, better access to diagnostic methods with high sensitivity as well as large-scale secondary prevention (prostate cancer screening at early stage before clinical manifestation). Secondary prevention is becoming more accessible and widely applied. The expected effect of prevention is to improve overall survival while the mortality trend is decreasing. The prevention success requires highly effective healthcare system that must manage additional burden which is a consequence of the need to provide optimal treatment and healthcare in a big group of cancer patients diagnosed in effective prevention programms. According to the National Cancer Registry (NCR) the number of incidence from year 1980 – 1731 cases rose in year 2013 to 12 162 cases. Apart from incidence and mortality rates, the 5-year survival is a significant factor for the assessment of a population healthcare and healthcare system efficiency. The prognosis related to prostate incidence is 22 344 men in year 2025 in comparison to 12 162 in year 2013 – that would be a double rise in incidence. CONCORD-2 results (years 1995-2009) showed, among the others, that cancer curability for some cancers, including prostate cancer improved. In year 2018 the results of CONCORD-3 were published (years 2000-2014) showing a rising trend in improvement in prostate cancer curability in Poland Objective. The objective was to analyse the 5-year survival in prostate cancer patients in Poland, and in each of 16 voivodships, with the focus on changes in years 2000 – 2014 in comparison to European trends. Material and Methods. The analysis was based on the 5-year net survival (estimated in CONCORD-3) in prostate cancer patients diagnosed in Poland (NCR national data) and in all Polish voivodships. The 5-year survival of prostate cancer patients and its changes in years 2000 – 2014 compared between 16 voivodships, Poland in total and 28 European countries. Results. In Poland in years 2010 – 2014 the 5-year survival in prostate cancer patients was 78.1%, and compared to years 2000 – 2004 rose by 9.3 percentage points. Despite a systematic improvement in survival the differences between individual voivodships in Poland remained. In 6 voivodships the survival was higher than average for Poland and ranged from 80 to 82%. The lowest survival was in Opolskie voivodship – 72.3%. On a European scale, the curability of prostate cancer at that time was over 90% (9 countries), while Poland was among 5 countries whose total survival rate was less than 80% (from 72.3% - Opolskie voivodship to 83.6% –- Pomeranian voivodship). Conclusions. The 5-year survival in prostate cancer patients in years 2010 – 2014 in Poland was significantly lower in comparison to Western Europe countries, and favourable trends on a regional level in Poland were too slow to overcome high differentiation in Europe. It is expected that changing the structure and organisation of cancer care in Poland into a modern National Oncology Network Comprehensive Cancer Care Network, together with the use of the experiences from European projects, including iPAAC and better financing will contribute to improvement in prostate cancer treatment in Poland.
Źródło:
Roczniki Państwowego Zakładu Higieny; 2020, 71, 4; 445-453
0035-7715
Pojawia się w:
Roczniki Państwowego Zakładu Higieny
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cardiovascular complications during the treatment of castration-resistant prostate cancer with the use of modern antiandrogens: abiraterone acetate and enzalutamide
Autorzy:
Grabysa, Radosław
Chmielewska, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/2047222.pdf
Data publikacji:
2021-09-13
Wydawca:
Medical Education
Tematy:
abiraterone acetate
enzalutamide
castration resistant prostate cancer
cardiovascular
Opis:
Modern antiandrogens: abiraterone acetate (inhibitor of CYP17 cytochrome) and enzalutamide (irreversible inhibitor of androgen receptor) are the drugs that are increasingly often administered in treatment of castration-resistant prostate cancer. Despite their clinical efficacy, especially in terms of prolonged survival and improved quality of life of patients, they pose of problem for a practicing oncologist such as possible cardiovascular complications (particularly arterial hypertension), which may lead to the cessation of this form of therapy. This article provides a brief overview of the mechanisms responsible for the above complications, including practical recommendations in the event such complications arise. A simple scheme of action for control of cardiovascular risk factors has been presented, which can improve the prognosis in this population of patients.
Źródło:
OncoReview; 2021, 11, 3; 61-67
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Abiraterone acetate - 10 clinically relevant facts
Autorzy:
Żołnierek, Jakub
Powiązania:
https://bibliotekanauki.pl/articles/2047213.pdf
Data publikacji:
2021-09-30
Wydawca:
Medical Education
Tematy:
prostate cancer
systemic therapy
hormone therapy
abiraterone acetate
Opis:
Prostate cancer is one of the most frequently diagnosed cancers in men. Number of newly diagnosed cases is increasing due to several factors and the most important ones seem to be: population ageing and more sensitive diagnostic procedures. Secondary – the higher efficacy of treatment with its influence on improving patients’ overall survival and the specific mechanism of action of drugs used in systemic therapy lead to growing population of men suffering from prostate cancer in general and, specifically – patients with castration resistance. It is hormone therapy to play the key role in systemic treatment of prostate cancer with increasing significance of novel drugs focused on inhibition of molecular signal transduction mediated by androgen receptor. Abiraterone acetate is the representative of this therapeutic class. The paper describes the most clinically relevant data regarding the drug.
Źródło:
OncoReview; 2021, 11, 3; 80-84
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 51

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies